ADAM12 and autoimmune disease: Given that disparate immune responses (Th1 vs. Th17) are associated with different categories of autoimmune disease—and even between subsets of patients in a specific autoimmune disease, such as in MS51—future studies should determine whether ADAM12 is a potential target that represses tissue-specific inflammation, particularly in those with a Th1-mediated disease.